RECENT NEWS

The Institute of Biomedical Science (IBMS) has published a new positioning paper calling for the controlled, independently evaluated implementation of AI-assisted digital cytology within NHS cervical screening programmes.

Tens of thousands of young people have received the first of a life-saving double dose of the meningitis B vaccine within just two weeks of the NHS launching its biggest ever catch-up campaign for the virus.

The Medical Research Council (MRC) has invested £50 million into the study of mitochondrial diseases to improve treatments.

POCT Innovators’ next Power to Disrupt one-day event takes place in Oxford on Monday 16 November, and booking is open now, with free places on offer to NHS workers.

A pioneering pathology technology developed by the National Pathology Imaging Co‑operative (NPIC) is set for international deployment after securing a commercial agreement with precision cancer diagnostics firm Epredia.

In May, over 100 delegates and representatives from 21 commercial companies descended on the Royal Air Force Museum in Hendon, North London for the 41st iteration of the British Society for Microbial Technology (BSMT) Annual Microbiology Conference.

The development of artificial intelligence in medical technology is usually discussed as a technical challenge. For companies attempting to bring AI-enabled medical devices to market, however, further constraints are becoming increasingly important.

illumiSonics, a medical technology company commercialising label-free tissue imaging, has launched a prospective clinical validation study at Sunnybrook Health Sciences Centre evaluating its Multi-Laser Imaging (MLI) platform for skin cancer margin assessment during Mohs micrographic surgery.

Epredia, a global leader in precision cancer diagnostics solutions, has announced an agreement with Canada-based manufacturer Lab Improvements to bring intelligent archiving for tissue samples to US pathology laboratories.

One Biosciences, a company pioneering clinical-grade single-cell tumour profiling, has announced data establishing that single-cell RNA expression profiles can be generated from standard, formalin-fixed paraffin wax-embedded (FFPE) pathology specimens obtained in routine cancer care using its proprietary platform OneMap.

bioAffinity Technologies has announced a collaboration with Pictor to support development and commercialisation of bioAffinity Technologies’ next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and chronic obstructive pulmonary disease (COPD).

The Institute of Tropical Medicine (ITM) in Antwerp is receiving an additional €2 million in funding from the Belgian Directorate-General for Development Cooperation and Humanitarian Aid (DGD) to strengthen research and control efforts against the mpox virus (pictured) in the Democratic Republic of the Congo (DRC).

Submissions for Lab Innovations’ Lab Awards, which recognise the achievements and successes of individuals, laboratories and suppliers over the past year, remain open until August 14.

Molecular diagnostics firm Cepheid will unveil the third generation of the GeneXpert system at the upcoming Association for Diagnostics & Laboratory Medicine (ADLM) Annual Scientific Meeting.

En Carta Diagnostics has raised €5 million in financing to fund regulatory certification, industrialisation and commercial launch in Europe and the US of its at-home molecular diagnostics.

Researchers at Loughborough University are uncovering new evidence that exercise may help counteract the cancer-promoting effects of fat cells. The research uses advanced 3D cell culture models and bioluminescence-based assay technology from Promega to generate physiologically relevant data that traditional 2D culture models cannot replicate.

The National Pathology Imaging Co-operative (NPIC) has gone live with a new hospital site, bringing the total number of connected sites across England to 15. Further sites are expected to join later this year.

Revvity has announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB testing for large-volume clinical laboratories, enabling a reliable, accurate solution for latent tuberculosis (TB) detection.

A new study from a team including University of Nebraska–Lincoln researchers is the first to show metabolites produced by certain bacteria in the gut can positively impact the body’s immune response to cancer.

The Government has shared a new Quality Strategy for NHS-funded Care in England. Developed by the National Quality Board, the strategy aims to put quality at the centre of the NHS’s work, providing a new structured approach to making quality the organising principle for all NHS activity in England over the next decade.